Morgan Stanley Paratek Pharmaceuticals, Inc. Transaction History

Morgan Stanley

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$1.52 - $2.8 $312,229 - $575,159	-205,414 Reduced 64.83%	111,434 $246,000
Q1 2023 May 15, 2023	BUY	$1.37 - $2.54 $241,278 - $447,334	176,116 Added 125.14%	316,848 $804,000
Q4 2022 Feb 14, 2023	SELL	$1.67 - $2.51 $93,449 - $140,454	-55,958 Reduced 28.45%	140,732 $263,000
Q3 2022 Nov 14, 2022	SELL	$1.96 - $2.93 $24,605 - $36,783	-12,554 Reduced 6.0%	196,690 $505,000
Q2 2022 Oct 27, 2022	BUY	$1.73 - $3.09 $194,829 - $347,989	112,618 Added 116.55%	209,244 $405,000
Q2 2022 Aug 15, 2022	BUY	$1.73 - $3.09 $194,829 - $347,989	112,618 Added 116.55%	209,244 $405,000
Q1 2022 Oct 27, 2022	SELL	$2.94 - $4.77 $331,096 - $537,187	-112,618 Reduced 53.82%	96,626 $286,000
Q1 2022 May 13, 2022	BUY	$2.94 - $4.77 $61,313 - $99,478	20,855 Added 27.52%	96,626 $286,000
Q4 2021 Feb 14, 2022	SELL	$4.07 - $5.3 $358,412 - $466,728	-88,062 Reduced 53.75%	75,771 $340,000
Q3 2021 Nov 15, 2021	BUY	$4.7 - $7.24 $770,015 - $1.19 Million	163,833 New	163,833 $795,000

1.54M

Ticker PRTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,862,500
Description
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectru...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.